Work

Prevalence of Wilson’s disease in Poland

Year: 2026
Type: article
Study design: Observational Study
Abstract: INTRODUCTION: The prevalence of Wilson's disease (WD) varies across the globe and differs in European countries. It is higher in southern Europe, and lower in northern and eastern Europe, with expected prevalence rise through 2030. OBJECTIVES: We aimed to assess the real‑world prevalence of WD in Poland. PATIENTS AND METHODS: The number of health services and prescription data for D‑penicillamine and zinc sulphate were retrieved from the National Health Fund (NFZ), while sick leave and disability pension records were obtained from the Social Insurance Institution (ZUS). RESULTS: E83.0 code, who received at least 1 service from the NFZ, varied from 355 in 2013 to 1160 in 2025. The estimated prevalence of patients with WD in the Polish population in 2025 was 30.94 per 1 million (1 per 32 318 inhabitants). The number of patients with WD who filled at least 1 prescription for D‑penicillamine ranged from 257 to 391 per year, and the estimated number of patients treated with zinc sulphate ranged from 59 to 629 per year. The majority of patients were reported in the biggest cities: Warsaw, followed by Kraków and Wrocław. There was a sharp decline in disability pensions, falling from 105 in 2016 to just 20 in 2024, while the number of sick‑leave days continued to increase. CONCLUSIONS: Estimated WD prevalence in Poland is comparable to that in the neighboring countries. Many patients remain professionally active. Expanding screening programs may improve early detection.
Language: English
Field: Nursing
Open Access status: diamond
OpenAlex ID: W7204209967
FWCI:
Cites: 41
Cited by:
Related to: 10